

1 **Viral dynamics of acute SARS-CoV-2 infection**

2

3 Stephen M. Kissler*¹, Joseph R. Fauver*², Christina Mack*^{3,4}, Scott W. Olesen¹, Caroline Tai³, Kristin Y.
4 Shiue^{3,4}, Chaney C. Kalinich², Sarah Jednak⁵, Isabel M. Ott², Chantal B.F. Vogels², Jay Wohlgemuth⁶,
5 James Weisberger⁷, John DiFiori⁸, Deverick J. Anderson⁹, Jimmie Mancell¹⁰, David D. Ho¹¹, Nathan D.
6 Grubaugh^{†2}, Yonatan H. Grad^{†1}

7

8 ¹ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health,
9 Boston, MA

10 ² Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT

11 ³ IQVIA, Real World Solutions, Durham, NC

12 ⁴ Department of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, NC

13 ⁵ Department of Health Management and Policy, University of Michigan School of Public Health, Ann
14 Arbor, MI

15 ⁶ Quest Diagnostics, San Juan Capistrano, CA

16 ⁷ Bioreference Laboratories, Elmwood Park, NJ

17 ⁸ Hospital for Special Surgery, and the National Basketball Association, New York, NY

18 ⁹ Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC

19 ¹⁰ Department of Medicine, University of Tennessee Health Science Center, Memphis, TN

20 ¹¹ Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and
21 Surgeons, New York, NY

22

23

24 * denotes equal contribution

25 † denotes co-senior authorship

26

27 Correspondence and requests for materials should be addressed to:

28 Email: ygrad@hsph.harvard.edu

29 Telephone: 617.432.2275

30

31 **Abstract**

32

33 **Background.** SARS-CoV-2 infections are characterized by viral proliferation and clearance phases and
34 can be followed by low-level persistent viral RNA shedding. The dynamics of viral RNA concentration,
35 particularly in the early stages of infection, can inform clinical measures and interventions such as test-
36 based screening.

37

38 **Methods.** We used prospective longitudinal RT-qPCR testing to measure the viral RNA trajectories for 68
39 individuals during the resumption of the 2019-20 National Basketball Association season. For 46
40 individuals with acute infections, we inferred the peak viral concentration and the duration of the viral
41 proliferation and clearance phases.

42

43 **Findings.** According to our mathematical model, we found that viral RNA concentrations peaked an
44 average of 3.3 days (95% credible interval [2.5, 4.2]) after first possible detectability at a cycle threshold
45 value of 22.3 [20.5, 23.9]. The viral clearance phase lasted longer for symptomatic individuals (10.9 days
46 [7.9, 14.4]) than for asymptomatic individuals (7.8 days [6.1, 9.7]). A second test within 2 days after an
47 initial positive PCR substantially improves certainty about a patient's infection phase. The effective
48 sensitivity of a test intended to identify infectious individuals declines substantially with test turnaround
49 time.

50

51 **Conclusions.** SARS-CoV-2 viral concentrations peak rapidly regardless of symptoms. Sequential tests can
52 help reveal a patient's progress through infection stages. Frequent rapid-turnaround testing is needed to
53 effectively screen individuals before they become infectious.

54 **Introduction.**

55

56 A critical strategy to curb the spread of SARS-CoV-2 is to rapidly identify and isolate infectious individuals.
57 Because symptoms are an unreliable indicator of infectiousness and infections are frequently
58 asymptomatic¹, testing is key to determining whether a person is infected and may be contagious. Real time
59 quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) tests are the gold standard for
60 detecting SARS-CoV-2 infection. Normally, these tests yield a binary positive/negative diagnosis based on
61 detection of viral RNA. However, they can also quantify the viral titer via the cycle threshold (Ct). The Ct
62 is the number of thermal cycles needed to amplify sampled viral RNA to a detectable level: the higher the
63 sampled viral RNA concentration, the lower the Ct. This inverse correlation between Ct and viral
64 concentration makes RT-qPCR tests far more valuable than a binary diagnostic, as they can be used to
65 reveal a person's progress through key stages of infection², with the potential to assist clinical and public
66 health decision-making. However, the dynamics of the Ct during the earliest stages of infection, when
67 contagiousness is rapidly increasing, have been unclear, because diagnostic testing is usually performed
68 after the onset of symptoms, when viral RNA concentration has peaked and already begun to decline, and
69 performed only once^{3,4}. Without a clear picture of the course of SARS-CoV-2 viral concentrations across
70 the full duration of acute infection, it has been impossible to specify key elements of testing algorithms
71 such as the frequency of rapid at-home testing⁵ that will be needed to reliably screen infectious individuals
72 before they transmit infection. Here, we fill this gap by analyzing the prospective longitudinal SARS-CoV-
73 2 RT-qPCR testing performed for players, staff, and vendors during the resumption of the 2019-20 National
74 Basketball Association (NBA) season.

75

76 **Methods.**

77 Data collection.

78 The study period began in teams' local cities from June 23rd through July 9th, 2020, and testing continued
79 for all teams as they transitioned to Orlando, Florida through September 7th, 2020. A total of 68 individuals
80 (90% male) were tested at least five times during the study period and recorded at least one positive test
81 with Ct value <40. Most (85%) of consecutive tests were recorded within one day of each other and fewer

82 than 3% of the intervals between consecutive tests exceeded 4 days (**Supplemental Figure 1**). Many
83 individuals were being tested daily as part of Orlando campus monitoring. Due to a lack of new infections
84 among players and team staff after clearing quarantine in Orlando, all players and team staff included in
85 the results pre-date the Orlando phase of the restart. A diagnosis of “acute” or “persistent” infection was
86 abstracted from physician records. “Acute” denoted a likely new infection. “Persistent” indicated the
87 presence of virus in a clinically recovered individual, likely due to infection that developed prior to the
88 onset of the study. There were 46 acute infections; the remaining 22 individuals were assumed to be
89 persistently shedding SARS-CoV-2 RNA due to a known infection that occurred prior to the study period⁶.
90 This persistent RNA shedding can last for weeks after an acute infection and likely represented non-
91 infectious viral RNA⁷. Of the individuals included in the study, 27 of the 46 with acute infections and 40
92 of the 68 overall were from staff and vendors. The Ct values for all tests for the 68 individuals included in
93 the analysis with their designations of acute or persistent infection are depicted in **Supplemental Figures**
94 **2–5**. A schematic diagram of the data collection and analysis pipeline is given in **Figure 1**.

95

96 Statistical analysis.

97 Due to imperfect sampling, persistent viral shedding, and test uncertainty near the limit of detection, a
98 straightforward analysis of the data would be insufficient to reveal the duration and peak magnitude of the
99 viral trajectory. Imperfect sampling would bias estimates of the peak viral concentration towards lower
100 concentrations/higher Ct values since the moment of peak viral concentration is unlikely to be captured.
101 Persistent shedding and test uncertainty would bias estimates of the trajectory duration towards longer
102 durations of infection. To address these problems, we used a Bayesian statistical model to infer the peak Ct
103 value and the durations of the proliferation and clearance stages for the 46 acute infections (**Figure 1**;
104 **Supplemental Methods**). We assumed that the viral concentration trajectories consisted of a proliferation
105 phase, with exponential growth in viral RNA concentration, followed by a clearance phase characterized
106 by exponential decay in viral RNA concentration⁸. Since Ct values are roughly proportional to the negative
107 logarithm of viral concentration², this corresponds to a linear decrease in Ct followed by a linear increase.
108 We therefore constructed a piecewise-linear regression model to estimate the peak Ct value, the time from
109 infection onset to peak (*i.e.*, the duration of the proliferation stage), and the time from peak to infection

110 resolution (*i.e.*, the duration of the clearance stage). This allowed us to separate the viral trajectories into
111 the three distinct phases of proliferation (from the onset of detectability to the peak viral concentration, or
112 t_0 to t_p in **Supplemental Figure 6**), clearance (from the peak viral concentration to the resolution of acute
113 infection, or t_p to t_r in **Supplemental Figure 6**), and persistence (lasting indefinitely after the resolution of
114 acute infection, or after t_r in **Supplemental Figure 6**; see also **Figure 1**). Note that for the 46 individuals
115 with acute infections, the persistence phase is identified using the viral trajectory model, whereas for the
116 22 other infections the entire series of observations was classified as ‘persistent’ due to clinical evidence of
117 a probable infection prior to the start of the study period. We estimated the parameters of the regression
118 model by fitting to the available data using a Hamiltonian Monte Carlo algorithm⁹ yielding simulated draws
119 from the Bayesian posterior distribution for each parameter. Full details on the fitting procedure are given
120 in the **Supplemental Methods**. Code is available at <https://github.com/gradlab/CtTrajectories>.

121

122 Inferring stage of infection.

123 Next, we determined whether individual or paired Ct values can reveal whether an individual is in the
124 proliferation, clearance, or persistent stage of infection. To assess the predictive value of a single Ct value,
125 we extracted all observed Ct values within a 5-unit window (*e.g.*, between 30 and 35 Ct) and measured how
126 frequently these values sat within the proliferation stage, the clearance stage, or the persistent stage. We
127 measured these frequencies across 10,000 posterior parameter draws to account for that fact that Ct values
128 near stage transitions (*e.g.*, near the end of the clearance stage) could be assigned to different infection
129 stages depending on the parameter values (see **Figure 1**, bottom-right). We did this for 23 windows with
130 midpoint spanning from Ct = 37.5 to Ct = 15.5 in increments of 1 Ct.

131

132 To calculate the probability that a Ct value sitting within the 5-unit window corresponded to an acute
133 infection (*i.e.*, either the proliferation or the clearance stage), we summed the proliferation and clearance
134 frequencies for all samples within that window and divided by the total number of samples in the window.
135 We similarly calculated the probability that a Ct sitting within the 5-unit window corresponded to just the
136 proliferation phase.

137

138 To assess the information gained by conducting a second test within two days of an initial positive, we
139 restricted our attention to all samples that had a subsequent sample taken within two days. We repeated the
140 above calculations for (a) consecutive tests with decreasing Ct and (b) consecutive tests with increasing Ct.
141 That is, we measured the frequency with which a given Ct value sitting within a 5-unit window, followed
142 by a second test with either lower or higher Ct, sat within with the proliferation, clearance, or persistence
143 stages.

144

145 Measuring the effective sensitivity of screening tests.

146 The sensitivity of a test is defined as the probability that the test correctly identifies an individual who is
147 positive for some criterion of interest. For clinical diagnostic SARS-CoV-2 tests, the criterion of interest is
148 current infection with SARS-CoV-2. Alternatively, a common goal is to predict infectiousness at some
149 point in the future, as in the context of test-based screening prior to a social gathering. The ‘effective
150 sensitivity’ of a test in this context (*i.e.*, its ability to predict future infectiousness) may differ substantially
151 from its clinical sensitivity (*i.e.*, its ability to detect current infection). A test’s effective sensitivity depends
152 on its inherent characteristics, such as its limit of detection and sampling error rate, as well as the viral
153 dynamics of infected individuals.

154

155 To illustrate this, we estimated the effective sensitivity of (a) a test with limit of detection of 40 Ct and a
156 1% sampling error probability (akin to RT-qPCR), and (b) a test with limit of detection of 35 Ct and a 5%
157 sampling error probability (akin to some rapid antigen tests). We measured the frequency with which such
158 tests would successfully screen an individual who would be infectious at the time of a gathering when the
159 test was administered between 0 and 3 days prior to the gathering, given viral trajectories informed by the
160 longitudinal testing data (see schematic in **Figure 1**). To accomplish this, we drew 1,000 individual-level
161 viral concentration trajectories from the fitted model, restricting to trajectories with peak viral concentration
162 above a given infectiousness threshold (any samples with peak viral concentration below the infectiousness
163 threshold would never be infectious and so would not factor into the sensitivity calculation). For the main
164 analysis, we assumed that the infectiousness threshold was at 30 Ct¹⁰. In a supplementary analysis, we also
165 assessed infectiousness thresholds of 35 and 20 Ct. We drew onset-of-detectability times (*i.e.*, the onset of

166 the proliferation stage) according to a random uniform distribution so that each person would have a Ct
167 value exceeding the infectiousness threshold at the time of the gathering. Then, we calculated the fraction
168 of trajectories that would be successfully screened using (a) a test with limit of detection of 40 Ct and (b) a
169 limit of detection of 35 Ct, administered between 0 and 3 days prior to the gathering. Full details are given
170 in the **Supplemental Methods** and **Supplemental Figure 7A**.

171
172 Next, we shifted attention from the individual to the gathering. We estimated the number of individuals
173 who would be expected to arrive at a 1,000-person gathering while infectious given each testing strategy
174 (40 Ct limit of detection with 1% false negative rate; 35 Ct limit of detection with 5% false negative rate)
175 assuming a 2% prevalence of PCR-detectable infection in the population. To do so, we again drew 1,000
176 individual-level viral concentration trajectories from the fitted model and drew onset-of-detectability times
177 according to a random uniform distribution from the range of possible times that would allow for the person
178 to have detectable virus ($Ct < 40$) during the gathering. We counted the number of people who would have
179 been infectious at the gathering (a) in the absence of testing and (b) given a test administered between 0
180 and 3 days prior to the gathering. As before, we assumed that infectiousness corresponded to a Ct value of
181 30 for the main analysis and considered infectiousness thresholds of 35 Ct and 20 Ct in a supplemental
182 analysis. Full details are given in the **Supplemental Methods** and **Supplemental Figure 7B**. To facilitate
183 the exploration of different scenarios, we have generated an online tool ([https://stephenkissler.shinyapps.io](https://stephenkissler.shinyapps.io/shiny/)
184 [/shiny/](https://stephenkissler.shinyapps.io/shiny/)) where users can input test and population characteristics and calculate the effective sensitivity and
185 expected number of infectious individuals at a gathering.

186 187 **Results.**

188
189 Of the 46 individuals with acute infections, 13 reported symptoms at the time of diagnosis; the timing of
190 the onset of symptoms was not recorded. The median number of positive tests for the 46 individuals was 3
191 (IQR [2, 5]). The minimum recorded Ct value across the 46 individuals had mean 26.4 (IQR [23.2, 30.4]).
192 The recorded Ct values for the acute infections with individual-level piecewise linear regressions are
193 depicted in **Figure 2**.

194

195 Based on the viral trajectory model, the mean peak Ct value for symptomatic individuals was 22.3 (95%
196 credible interval [19.3, 25.3]), the mean duration of the proliferation phase was 3.4 days [2.0, 4.8], and the
197 mean duration of clearance was 10.9 days [7.9, 14.4] (**Figure 3**). This compares with 22.3 Ct [20.0, 24.4],
198 3.5 days [2.5, 4.5], and 7.8 days [6.1, 9.7], respectively, for individuals who did not report symptoms at the
199 time of diagnosis (**Figure 3**). This yielded a slightly longer overall duration of acute infection for
200 individuals who reported symptoms (14.3 days [11.0, 17.7]) vs. those who did not (11.2 days [9.4, 13.4]).
201 For all individuals regardless of symptoms, the mean peak Ct value, proliferation duration, clearance
202 duration, and duration of acute shedding were 22.3 Ct [20.5, 23.9], 3.3 days [2.5, 4.2], 8.5 days [6.9, 10.1],
203 and 11.7 days [10.1, 13.6] (**Supplemental Figure 8**). A full list of the model-inferred viral trajectory
204 parameters is reported in **Table 1**. There was a substantial amount of individual-level variation in the peak
205 Ct value and the proliferation and clearance stage durations (**Supplemental Figures 9–14**).

206

207 Using the full dataset of 68 individuals, we estimated the frequency with which a given Ct value was
208 associated with an acute infection (*i.e.*, the proliferation or clearance phase, but not the persistence phase),
209 and if so, the probability that it was associated with the proliferation stage alone. The probability of an acute
210 infection increased rapidly with decreasing Ct (increasing viral load), with Ct < 30 virtually guaranteeing
211 an acute infection in this dataset (**Figure 4A**). However, a single Ct value provided little information about
212 whether an acute infection was in the proliferation or the clearance stage (**Figure 4B**). This is unsurprising
213 since the viral trajectory must pass through any given value during both the proliferation and the clearance
214 stage. With roughly uniform sampling over time, a given Ct value is more likely to correspond to the
215 clearance stage simply because the clearance stage is longer.

216

217 We assessed whether a second test within two days of the first could improve these predictions. A positive
218 test followed by a second test with lower Ct (higher viral RNA concentration) was slightly more likely to
219 be associated with an active infection than a positive test alone (**Figure 4C**). Similarly, a positive test
220 followed by a second test with lower Ct (higher viral RNA concentration) was much more likely to be
221 associated with the proliferation phase than with the clearance phase (**Figure 4D**).

222

223 We next estimated how the effective sensitivity of a pre-event screening test declines with increasing time
224 to the event. For a test with limit of detection of 40 Ct and a 1% chance of sampling error, the effective
225 sensitivity declines from 99% when the test coincides with the start of the event to 76% when the test is
226 administered two days prior to the event (**Figure 5A**), assuming a threshold of infectiousness at 30 Ct¹⁰.
227 This two-day-ahead sensitivity is slightly lower than the effective sensitivity of a test with a limit of
228 detection at 35 Ct and a 5% sampling error administered one day before the event (82%), demonstrating
229 that limitations in testing technology can be compensated for by reducing turnaround time. Using these
230 effective sensitivities, we estimated the number of infectious individuals who would be expected to arrive
231 at a gathering with 1,000 people given a pre-gathering screening test and a 2% prevalence of infectiousness
232 in the population. Just as the effective sensitivity declines with time to the gathering, the predicted number
233 of infectious individuals rises with time to the gathering (**Figure 5B**) since longer delays between the
234 screening test and the gathering make it more likely that an individual will be undetectable at the time of
235 testing but infectious at the time of the event. Changing the infectiousness threshold modulates the
236 magnitude of the decline in effective sensitivity associated with longer testing delays; however, the overall
237 trend is consistent (**Supplemental Figure 18**).

238

239 **Discussion.**

240 We provide the first comprehensive data on the early-infection RT-qPCR Ct dynamics associated with
241 SARS-CoV-2 infection. We found that viral titers peak quickly, normally within 3 days of the first possible
242 RT-qPCR detection, regardless of symptoms. Our findings highlight that repeated PCR tests can be used to
243 infer the stage of a patient's infection. While a single test can inform on whether a patient is in the acute or
244 persistent viral RNA shedding stages, a subsequent test can help identify whether viral RNA concentrations
245 are increasing or decreasing, thus informing clinical care. For example, a patient near the beginning of their
246 infection may need to be isolated for different amounts of time than a patient near the end of their infection.
247 If a patient is at risk for complications, closer monitoring and more proactive treatment may be preferred
248 for patients near the start of infection than for those who are already nearing its resolution. We also show
249 that the effective sensitivity of pre-event screening tests declines rapidly with test turnaround time due to


250 the rapid progression from detectability to peak viral titers. Due to the transmission risk posed by large
251 gatherings¹¹, the trade-off between test speed and sensitivity must be weighed carefully. Our data offer the
252 first direct measurements capable of informing such decisions.

253
254 Our findings on the duration of SARS-CoV-2 viral RNA shedding expand on and agree with previous
255 studies¹²⁻¹⁴ and with observations that peak Ct does not differ substantially between symptomatic and
256 asymptomatic individuals³. While previous studies have largely relied on serial sampling of admitted
257 hospital patients, our study used prospective sampling of ambulatory infected individuals to characterize
258 complete viral dynamics for the presymptomatic stage and for individuals who did not report symptoms.
259 This allowed us to assess differences between the viral RNA proliferation and clearance stages for
260 individuals with and without reported symptoms. The similarity in the early-infection viral RNA dynamics
261 for both symptomatic and asymptomatic individuals underscores the need for SARS-CoV-2 screening
262 regardless of symptoms. The progression from a negative test to a peak Ct value 2-4 days later aligns with
263 modeling assumptions made in various studies^{15,16} to evaluate the potential effectiveness of frequent rapid
264 testing programs, strengthening the empirical bases for their findings. Taken together, the dynamics of viral
265 RNA shedding substantiate the need for frequent population-level SARS-CoV-2 screening and a greater
266 availability of diagnostic tests.

267
268 Our findings are limited for several reasons. The sample size is small, especially with respect to
269 symptomatic acutely infected individuals. The cohort does not constitute a representative sample from the
270 population, as it was a predominantly male, healthy, young population inclusive of professional athletes.
271 Viral trajectories may differ for individuals who have been vaccinated or who have been infected with
272 SARS-CoV-2 variants, which we were unable to assess due to the timeframe of our study. Some of the
273 trajectories were sparsely sampled, limiting the precision of our posterior estimates. Symptom reporting
274 was imperfect, particularly after initial evaluation as follow-up during course of disease was not systematic
275 for all individuals. As with all predictive tests, the probabilities that link Ct values with infection stages
276 (**Figure 4**) pertain to the population from which they were calibrated and do not necessarily generalize to
277 other populations for which the prevalence of infection and testing protocols may differ. Still, we anticipate

278 that the central patterns will hold across populations: first, that low Cts (<30) strongly predict acute
279 infection, and second, that a follow-up test collected within two days of an initial positive test can
280 substantially help to discern whether a person is closer to the beginning or the end of their infection. Our
281 study did not test for the presence of infectious virus, though previous studies have documented a close
282 inverse correlation between Ct values and culturable virus¹⁰. Our assessment of pre-event testing assumed
283 that individuals become infectious immediately upon passing a threshold and that this threshold is the same
284 for the proliferation and for the clearance phase. In reality, the threshold for infectiousness is unlikely to be
285 at a fixed viral concentration for all individuals and may be at a higher Ct/lower viral concentration during
286 the proliferation stage than during the clearance stage. Further studies that measure culturable virus during
287 the various stages of infection and that infer infectiousness based on contact tracing combined with
288 prospective longitudinal testing will help to clarify the relationship between viral concentration and
289 infectiousness.

290
291 To manage the spread of SARS-CoV-2, we must develop novel technologies and find new ways to extract
292 more value from the tools that are already available. Our results suggest that integrating the quantitative
293 viral RNA trajectory into algorithms for clinical management could offer benefits. The ability to chart a
294 patient's progress through their infection underpins our ability to provide appropriate clinical care and to
295 institute effective measures to reduce the risk of onward transmission. Marginally more sophisticated
296 diagnostic and screening algorithms may greatly enhance our ability to manage the spread of SARS-CoV-
297 2 using tests that are already available.




299

300


301 **Figure 1. Illustration of the analysis pipeline.** Combined anterior nares and oropharyngeal swabs were tested using a RT-qPCR
 302 assay to generate longitudinal Ct values ('Raw data', red points) for each person. Using a statistical model (see **Supplemental**
 303 **Figure 6** for a schematic of the model), we estimated Ct trajectories consistent with the data, represented by the thin lines under
 304 the '**Model fits**' heading. These produced posterior probability distributions for the peak Ct value, the duration of the proliferation
 305 phase (first potential detectability of infection to peak Ct), and the duration of the clearance phase (peak Ct to resolution of acute
 306 infection) for each person. We estimated population means for these quantities (under heading "Population estimates"). The model
 307 fits also allowed us to determine how frequently a given Ct value or pair of Ct values within a five-unit window (blue bars, under
 308 heading "Predicting infection from Ct") was associated with the proliferation phase, the clearance phase, or a persistent infection.
 309 Finally, the model fits allowed us to measure the 'effective sensitivity' of a test for predicting future infectiousness. The schematic
 310 illustration titled '**Measuring effective sensitivity**' depicts the relationship between testing lags and the ability to detect infectious
 311 individuals at a gathering. The illustrated viral trajectory surpasses the infectiousness threshold (dotted line) at the time of the
 312 gathering (vertical grey bar), so unless this individual is screened by a pre-gathering test, s/he would attend the event while
 313 infectious. One day prior to the gathering, the individual could be detected by either a rapid test or a PCR test. Two days prior to
 314 the event, the individual could be detected by a PCR test but not by a rapid test. Three days prior to the event, neither test would
 315 detect the individual.

316



317
318

319 **Figure 2. Reported Ct values with individual-level piecewise linear fits.** Ct values (points) for the 46 acute infections aligned
320 by the date when the minimum Ct was recorded for each individual. Lines depict the best-fit piecewise linear regression lines for
321 each individual with breakpoint at day 0. Red points/lines represent individuals who reported symptoms and blue points/lines
322 represent individuals who did not report symptoms. Five positive tests were omitted that occurred >20 days prior to the individual's
323 minimum Ct value, all of which had Ct > 35. The vertical axis on the right-hand side gives the conversion from Ct values to RNA
324 concentration.



325

326 **Figure 3. Peak Ct value and infection stage duration distributions according to symptoms reported at time of diagnosis.**
327 Posterior distributions obtained from 2,000 simulated draws from the posterior distributions for mean peak Ct value (A), mean
328 duration of the proliferation stage (first potential infection detectability to peak Ct, B), mean duration of the clearance stage (peak
329 Ct to resolution of acute RNA shedding, C), and total duration of acute shedding (D) across the 46 individuals with an acute
330 infection. The distributions are separated according to whether the person reported symptoms (red, 13 individuals) or did not report
331 symptoms (blue, 33 individuals). The mean Ct trajectory corresponding to the mean values for peak Ct, proliferation duration, and
332 clearance duration for symptomatic vs. asymptomatic individuals is depicted in (E) (solid lines), where shading depicts the 90%
333 credible intervals.

334


335
336
337
338
339
340

Table 1. Viral dynamic parameters, overall and separated by reported symptoms. Population sizes for each category are: symptoms, $N=13$; no symptoms, $N=33$; overall, $N=46$.

*Symptom reporting was imperfect as follow-up during course of disease was not systematic for all individuals.


Parameter	Mean, symptoms* [95% CI]	Mean, no symptoms* [95% CI]	Overall mean [95% CI]
Peak Ct	22.2 [19.1, 25]	22.4 [20.2, 24.5]	22.4 [20.7, 24]
Peak viral concentration (log RNA copies/ml/day)	7.6 [6.8, 8.4]	7.5 [7, 8.1]	7.5 [7.1, 8]
Proliferation duration (days)	3.3 [1.9, 5.1]	3.4 [2.5, 4.5]	3.2 [2.4, 4.2]
Proliferation rate (Ct/day)	5.6 [3.4, 9.3]	5.2 [3.8, 7.1]	5.6 [4.2, 7.3]
Proliferation rate (log RNA copies/ml/day)	1.6 [0.9, 2.6]	1.5 [1.0, 2.0]	1.5 [1.2, 2]
Clearance duration (days)	10.9 [7.8, 14.2]	7.8 [6.1, 9.7]	8.5 [6.8, 10.2]
Clearance rate (Ct/day)	1.7 [1.2, 2.4]	2.3 [1.7, 3]	2.1 [1.7, 2.6]
Clearance rate (log RNA copies/ml/day)	0.5 [0.3, 0.7]	0.6 [0.5, 0.8]	0.6 [0.5, 0.7]
Infection duration (days)	14.3 [11, 17.8]	11.2 [9.4, 13.3]	11.7 [9.9, 13.5]

341



342

343 **Figure 4. Relationship between single/paired Ct values and infection stage.** Probability that a given Ct value lying within a 5-
344 unit window (horizontal axis) corresponds to an acute infection (A, C) or to the proliferation phase of infection assuming an acute
345 infection (B, D). Sub-figures A and B depict the predictive probabilities for a single Ct value, while sub-figures C and D depict the
346 predictive probabilities for a positive test paired with a subsequent test with either lower (red) or higher (blue) Ct. The curves are
347 LOESS smoothing curves to better visualize the trends. Error bars represent the 90% Wald confidence interval.
348



349

350 **Figure 5. Effective sensitivity and expected number of infectious event attendees for tests with varying sensitivity.** A:
351 Effective sensitivity for a test with limit of detection of 40 Ct and 1% sampling error probability (red) and 35 Ct and 5% sampling
352 error probability (blue). B: Number of infectious individuals expected to attend an event of size 1,000 assuming a population
353 prevalence of 2% infectious individuals for a test with limit of detection of 40 Ct and 1% sampling error probability (red) and 35
354 Ct and 5% sampling error probability (blue). Shaded bands represent 90% prediction intervals generated from the quantiles of
355 1,000 simulated events and capture uncertainty both in the number of infectious individuals who would arrive at the event in the
356 absence of testing and in the probability that the test successfully identifies infectious individuals. The dashed line depicts the
357 expected number of infectious individuals who would attend the gathering in the absence of testing.

358 **References**

- 359 1. Furukawa NW, Brooks JT, Sobel J. Evidence Supporting Transmission of Severe Acute
360 Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic. *Emerg Infect Dis.*
361 2020;26(7). doi:10.3201/eid2607.201595
- 362 2. Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value.
363 *Clin Infect Dis.* 2020;02115(Xx):1-3. doi:10.1093/cid/ciaa619
- 364 3. Walsh KA, Jordan K, Clyne B, et al. SARS-CoV-2 detection, viral load and infectivity over the
365 course of an infection. *J Infect.* 2020;81(3):357-371. doi:10.1016/j.jinf.2020.06.067
- 366 4. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or Nasopharyngeal Swab Specimens
367 for Detection of SARS-CoV-2. *N Engl J Med.* 2020;February(Coorespondance):NEJMc2016359.
368 doi:10.1056/NEJMc2016359
- 369 5. Larremore DB, Wilder B, Lester E, et al. Test sensitivity is secondary to frequency and turnaround
370 time for COVID-19 surveillance. *Sci Adv.* 2020. doi:10.1126/sciadv.abd5393
- 371 6. Mack C, DiFiori J, Tai C. SARS-CoV-2 Transmission Risk Among National Basketball
372 Association Players, Staff, and Vendors Exposed to Individuals With Positive COVID-19 Test
373 Results After Recovery During the NBA's 2020 Regular and Postseason in Orlando. *JAMA Intern*
374 *Med.* 2021;In Press.
- 375 7. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: A Preliminary Study From 56
376 COVID-19 Patients. *Clin Infect Dis.* April 2020. doi:10.1093/cid/ciaa460
- 377 8. Cleary B, Hay JA, Blumenstiel B, Gabriel S, Regev A, Mina MJ. Efficient prevalence estimation
378 and infected sample identification with group testing for SARS-CoV-2. *medRxiv.* 2020.
- 379 9. Carpenter B, Gelman A, Hoffman MD, et al. Stan : A Probabilistic Programming Language. *J Stat*
380 *Softw.* 2017;76(1). doi:10.18637/jss.v076.i01
- 381 10. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-
382 PCR cycle threshold values in cases of COVID-19, England, January to May 2020. *Euro Surveill.*
383 2020;25(32):1-5. doi:10.2807/1560-7917.ES.2020.25.32.2001483
- 384 11. Cevik M, Marcus J, Buckee C, Smith T. SARS-CoV-2 Transmission Dynamics Should Inform
385 Policy. *SSRN Electron J.* 2020. doi:10.2139/ssrn.3692807
- 386 12. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV-1 and
387 MERS-CoV viral load dynamics, duration of viral shedding and infectiousness: a living systematic
388 review and meta-analysis. *medRxiv.* 2020.
- 389 13. Houlihan C, Vora N, Byrne T, et al. SARS-CoV-2 virus and antibodies in front-line Health Care
390 Workers in an acute hospital in London: preliminary results from a longitudinal study. *medRxiv.*
391 2020.
- 392 14. Lee S, Kim T, Lee E, et al. Clinical Course and Molecular Viral Shedding Among Asymptomatic
393 and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the
394 Republic of Korea. *JAMA Intern Med.* 2020;180(11):1447. doi:10.1001/jamainternmed.2020.3862
- 395 15. Larremore DB, Wilder B, Lester E, et al. Test sensitivity is secondary to frequency and turnaround
396 time for COVID-19 surveillance. *medRxiv.* 2020:2020.06.22.20136309.
397 doi:10.1101/2020.06.22.20136309
- 398 16. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to Permit
399 the Safe Reopening of College Campuses in the United States. *JAMA Netw Open.*
400 2020;3(7):e2016818. doi:10.1001/jamanetworkopen.2020.16818
- 401 17. U.S. Food and Drug Administration. *Quest Diagnostics Infectious Disease, Inc. ("Quest*
402 *Diagnostics") SARS-CoV-2 RNA Qualitative Real-Time RT-PCR Emergency Use Authorization.*
403 Washington, DC; 2020.
- 404 18. U.S. Food and Drug Administration. *Roche Molecular Systems, Inc. Cobas SARS-CoV-2*
405 *Emergency Use Authorization.* Washington, DC; 2020.
- 406 19. Kudo E, Israelow B, Vogels CBF, et al. Detection of SARS-CoV-2 RNA by multiplex RT-qPCR.
407 Sugden B, ed. *PLOS Biol.* 2020;18(10):e3000867. doi:10.1371/journal.pbio.3000867
- 408 20. Ott IM, Vogels C, Grubaugh N, Wyllie AL. *Saliva Collection and RNA Extraction for SARS-CoV-*
409 *2 Detection V.2.* New Haven, CT; 2020. [https://www.protocols.io/view/saliva-collection-and-rna-](https://www.protocols.io/view/saliva-collection-and-rna-extraction-for-sars-cov-bh6mj9c6)
410 [extraction-for-sars-cov-bh6mj9c6.](https://www.protocols.io/view/saliva-collection-and-rna-extraction-for-sars-cov-bh6mj9c6)
- 411 21. R Development Core Team R. R: A Language and Environment for Statistical Computing. Team
412 RDC, ed. *R Found Stat Comput.* 2011;1(2.11.1):409. doi:10.1007/978-3-540-74686-7

- 413 22. Vogels C, Fauver J, Ott IM, Grubaugh N. *Generation of SARS-COV-2 RNA Transcript Standards*
414 *for QRT-PCR Detection Assays.*; 2020. doi:10.17504/protocols.io.bdv6i69e
415
416

417 **Acknowledgements.** We thank the NBA, National Basketball Players Association (NBPA), and all of the
418 study participants who are committed to applying what they learned from sports towards enhancing public
419 health. In particular, we thank D. Weiss of the NBA for his continuous support and leadership. We are
420 appreciative of the discussions from the COVID-19 Sports and Society Working Group. We also thank D.
421 Larremore for comments on the manuscript, J. Hay and R. Niehus for suggestions on the statistical approach
422 and P. Jack and S. Taylor for laboratory support.

423
424 **Funding.** This study was funded by the NWO Rubicon 019.181EN.004 (CBFV), a clinical research
425 agreement with the NBA and NBPA (NDG), the Huffman Family Donor Advised Fund (NDG), Fast Grant
426 funding support from the Emergent Ventures at the Mercatus Center, George Mason University (NDG),
427 and the Morris-Singer Fund for the Center for Communicable Disease Dynamics at the Harvard T.H. Chan
428 School of Public Health (YHG).

429
430 **Role of funding source.** The funding sources did not play a role in the data collection, analysis, or
431 interpretation of this study.

432
433 **Author contributions.** SMK conceived of the study, conducted the statistical analysis, and wrote the
434 manuscript. JRF conceived of the study, conducted the laboratory analysis, and wrote the manuscript. CM
435 conceived of the study, collected the data, and wrote the manuscript. SWO conducted the statistical analysis.
436 CT analyzed the data and edited the manuscript. KYS analyzed the data and edited the manuscript. CCK
437 conducted the laboratory analysis and edited the manuscript. SJ conducted the laboratory analysis and
438 edited the manuscript. IMO conducted the laboratory analysis. CBFV conducted the laboratory analysis.
439 JW conducted laboratory analysis and edited the manuscript. JW conducted laboratory analysis and edited
440 the manuscript. JD conceived of the study and edited the manuscript. DJA contributed to data analysis and
441 edited the manuscript. JM contributed to data analysis and edited the manuscript. DDH conceived of the
442 study and edited the manuscript. NDG conceived of the study, oversaw the study, and wrote the manuscript.
443 YHG conceived of the study, oversaw the study, and wrote the manuscript.

444

445 **Competing interests.**

446 JW is an employee of Quest Diagnostics. JW is an employee of Bioreference Laboratories. NDG has a
447 consulting agreement for Tempus and receives financial support from Tempus to develop SARS-CoV-2
448 diagnostic tests. SMK, SWO, and YHG have a consulting agreement with the NBA.

449

450 **Supplementary Information** is available for this paper.